Compare · NRIX vs NVO
NRIX vs NVO
Side-by-side comparison of Nurix Therapeutics Inc. (NRIX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NRIX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 77.0x NRIX ($2.80B).
- Both names hit the wire about 9 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 20 for NRIX).
- Company
- Nurix Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $26.96+2.63%
- $48.65+3.65%
- Market cap
- $2.80B
- $215.46B
- 1M return
- -
- -2.08%
- 1Y return
- -
- -12.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 9
- 9
- Recent ratings
- 20
- 25
Nurix Therapeutics Inc.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; DeTIL-0255 for tumor infiltrating lymphocytes therapy; KINASE-CTM3 to treat T cell malignancies and autoimmune diseases; and LIGASE-INH2 for immuno-oncology. In addition, the company develops programs, such as COVID-CTM1, COVID-CTM2, and COVID-CTM3 that are designed for protein degradation to SARs CoV2 targets. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NRIX
- Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
- Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Nurix Therapeutics Inc.
- Chief Scientific Officer Hansen Gwenn exercised 4,356 shares at a strike of $1.86 and sold $108,900 worth of shares (4,356 units at $25.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Scientific Officer Hansen Gwenn sold $100,142 worth of shares (4,111 units at $24.36) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 117,227 units (SEC Form 4)
- Chief Financial Officer Van Houte Hans sold $115,989 worth of shares (4,761 units at $24.36) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 40,166 units (SEC Form 4)
- Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
- Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Chief Legal Officer Ring Christine exercised 5,787 shares at a strike of $8.72 and sold $382,358 worth of shares (16,589 units at $23.05) as part of a pre-agreed trading plan, decreasing direct ownership by 54% to 9,110 units (SEC Form 4)
- Chief Financial Officer Van Houte Hans converted options into 10,180 shares and sold $66,524 worth of shares (2,845 units at $23.38), increasing direct ownership by 20% to 44,927 units (SEC Form 4) (withholding obligation)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S